Otsuka v. Sun Pharma: ABILIFY MAINTENA® Patent Suit Dismissed Without Prejudice
Otsuka Pharmaceutical filed suit against Sun Pharmaceutical in the District of Delaware, asserting six patents covering ABILIFY MAINTENA® aripiprazole extended-release injectable suspension. The parties reached a resolution and stipulated dismissal without prejudice after 473 days, with the court retaining jurisdiction to enforce related settlement agreements.
Six-Patent ABILIFY MAINTENA® Dispute Ends in Negotiated Dismissal
On July 5, 2024, Otsuka Pharmaceutical Co., Ltd. filed a patent infringement action in the District of Delaware against Sun Pharmaceutical Industries, Inc., asserting six U.S. patents — US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2 — all directed to aripiprazole formulations and methods of use underlying the branded antipsychotic ABILIFY MAINTENA® (400 mg vials and pre-filled syringes). The suit is consistent with Hatch-Waxman ANDA litigation triggered by Sun’s attempt to seek FDA approval for a generic version of the product.
After 473 days, the parties filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims, counterclaims, and affirmative defenses without prejudice and without costs to either side. Critically, the court expressly retained jurisdiction to enforce the stipulated dismissal and the parties’ related agreements — language that strongly suggests a confidential licensing or settlement agreement was reached alongside the dismissal, even though its specific terms remain undisclosed in the public record.
A resolution within 473 days — before any substantive claim construction or trial proceedings — is consistent with a negotiated commercial arrangement, potentially including a licensed entry date for Sun’s generic. The without-prejudice designation means Sun’s ANDA-related validity and non-infringement positions were not adjudicated, and Otsuka’s patents were not tested on the merits. The specific terms of any underlying commercial agreement, including any authorized generic or market entry timeline, are not publicly available from the docket.
Filing to Dismissed without Prejudice in 473 days
473 days from filing to dismissal — consistent with a pre-trial negotiated resolution in Hatch-Waxman ANDA litigation
Dismissed without prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal — no merits ruling
A Rule 41(a)(1)(A)(ii) dismissal is a consensual procedural exit signed by both parties. Dismissal without prejudice means neither party obtained a judicial determination on validity, infringement, or enforceability. The court’s retention of jurisdiction to enforce ‘related agreements’ is a standard indicator that a confidential settlement or license was executed alongside the dismissal.
Procedural exit — no adjudicationWithout prejudice: what the public record does — and does not — tell us
A without-prejudice dismissal means Otsuka could theoretically refile if conditions breach, and Sun’s invalidity or non-infringement defenses were not surrendered. In Hatch-Waxman practice, this structure typically wraps a license granting Sun a future entry date. Whether such terms include royalties, market entry timing, or an authorized generic arrangement cannot be confirmed from the public docket.
No merits — terms undisclosedPatents survive unchallenged — commercial position preserved
Otsuka’s six asserted patents were not invalidated or adjudicated unenforceable. The without-prejudice structure and jurisdiction retention clause suggest Otsuka secured contractual protections governing Sun’s market access. ABILIFY MAINTENA® patent protection continues against third parties, and the outcome does not set any adverse precedent on the asserted claims.
Patents intact — no adverse rulingGeneric pathway likely negotiated — no invalidity win on record
Sun avoided a full Hatch-Waxman trial across six patents and did not obtain a court ruling invalidating or finding non-infringement of any asserted claim. However, the structured dismissal and court-retained jurisdiction suggest Sun achieved some negotiated certainty over its ANDA approval and future commercial entry. The absence of a merits ruling limits Sun’s ability to leverage this outcome in any related litigation.
Negotiated certainty — no precedent valueFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | Japanese pharmaceutical company — holder of ABILIFY MAINTENA® aripiprazole injectable patentsSearch in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | U.S. subsidiary of Sun Pharmaceutical; ANDA filer seeking generic aripiprazole injectable approvalSearch in Eureka ↗ |
| Plaintiff counsel | A. Sasha Hoyt | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Erin M. Sommers | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | James B. Monroe | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jeanette M. Roorda | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Laura E. Brashear | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Melanie Magdun | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Lauren Eiten | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara M. Metzler | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s operative language — dismissal of ‘all claims, counterclaims and affirmative defenses’ without prejudice and without costs — confirms this is a full procedural exit with no merits adjudication on any of the six asserted patents. The explicit retention of court jurisdiction to enforce ‘the parties’ related agreements resolving this matter’ is legally significant: it signals a binding underlying arrangement, likely a license, and preserves Otsuka’s ability to seek court enforcement if Sun deviates from agreed terms. Neither party’s substantive IP positions were determined.
US11400087B2 and 5 further patents — aripiprazole extended-release injectable formulations
The six asserted patents — US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2 — collectively protect formulation, composition, and method-of-treatment aspects of ABILIFY MAINTENA®, an extended-release injectable suspension of aripiprazole used in schizophrenia and bipolar disorder maintenance therapy. The patents span multiple application families and filing dates, reflecting Otsuka’s strategy of building layered, overlapping coverage across the product lifecycle in the long-acting injectable antipsychotic space.
The breadth of this portfolio — six patents across at least four distinct application families — makes ABILIFY MAINTENA® among the more heavily protected branded long-acting injectables in the CNS category. Any ANDA filer must address each asserted patent individually, significantly increasing litigation cost and settlement leverage for the innovator. For competitors developing aripiprazole injectable generics, the multi-layered formulation and method claims represent distinct design-around challenges, with method-of-treatment claims often the hardest to avoid without clinical differentiation.
Should you run an FTO against the ABILIFY MAINTENA® patent portfolio?
Any company developing, manufacturing, or commercializing an aripiprazole extended-release injectable suspension — or a closely related long-acting antipsychotic injectable — should treat this six-patent portfolio as a priority FTO target. The asserted patents cover formulation composition, suspension preparation, and methods of treatment, meaning both the product itself and the clinical use protocol may fall within claim scope. ANDA filers, contract manufacturers, and 505(b)(2) applicants targeting the 400 mg vial or pre-filled syringe format are at highest immediate risk.
PatSnap Eureka’s FTO Search Agent can map each of the six asserted patents against your candidate formulation, identify claim-by-claim coverage gaps, and surface related family members or continuation applications that may not yet be asserted. Eureka also tracks inter partes review filings and Orange Book listings linked to this portfolio, allowing R&D and legal teams to monitor the competitive IP landscape in real time as Otsuka’s prosecution strategy evolves.
Run a freedom-to-operate analysis on US11400087B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman aripiprazole injectable patent cases in Delaware
Cases involving ABILIFY MAINTENA® or aripiprazole extended-release injectable patents litigated in the District of Delaware against ANDA filers.
What this case signals for the aripiprazole injectable IP landscape
Six Otsuka patents, one ANDA challenger, and a pre-trial resolution — the pattern has broad implications for branded CNS injectable portfolios.
Multi-patent stacking is the dominant ABILIFY MAINTENA® defensive strategy
Otsuka asserted six patents spanning formulation, dosing, and method claims. This layered approach raises the cost and complexity of any ANDA challenge, forcing generic entrants to design around or negotiate across the entire portfolio rather than defeating a single claim. Companies planning generics in long-acting injectable antipsychotics should map all six patents before filing a paragraph IV certification.
Court jurisdiction retention signals an underlying license — monitor FDA Orange Book
The stipulation’s language retaining court jurisdiction over ‘related agreements’ is a strong marker of a licensing arrangement with a negotiated market entry date. IP teams tracking competitive timelines for aripiprazole injectables should monitor the FDA Orange Book for any consent judgment or patent expiry listings that may disclose Sun’s agreed entry window.
Otsuka v Sun — key questions answered
Otsuka asserted six U.S. patents: US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2. All patents cover aspects of ABILIFY MAINTENA® (aripiprazole for extended-release injectable suspension) in 400 mg vials and pre-filled syringes, spanning formulation, composition, and method-of-treatment claims.
The parties filed a Rule 41(a)(1)(A)(ii) stipulated dismissal without prejudice, indicating a negotiated resolution. The court’s retention of jurisdiction to enforce ‘related agreements resolving this matter’ strongly suggests the parties entered a confidential license or settlement. No merits ruling on any of the six asserted patents was issued.
Not necessarily. A without-prejudice dismissal paired with court jurisdiction retention over ‘related agreements’ typically signals a licensing arrangement that may specify a future market entry date for Sun. The terms are confidential and not available from the public docket. Monitoring the FDA Orange Book for updated patent listings or consent judgments may provide indirect timing signals.
ABILIFY MAINTENA® is an extended-release injectable suspension of aripiprazole, a second-generation antipsychotic, indicated for schizophrenia and bipolar disorder maintenance. Its long-acting injectable format commands a significant commercial premium over oral formulations, making it a high-value generic target. Otsuka has protected the product with multiple overlapping patents, triggering Hatch-Waxman litigation when ANDA filers submit paragraph IV certifications.
Yes. A without-prejudice dismissal under Rule 41(a)(1)(A)(ii) does not bar Otsuka from refiling. If Sun launches its generic aripiprazole injectable outside any agreed terms, or if an underlying license is breached, Otsuka could refile infringement claims. The court’s retained jurisdiction also provides a direct enforcement mechanism for the parties’ related agreements without requiring a new suit.
PatSnap Eureka searches patents and litigation data to answer instantly.